Literature DB >> 9217598

Vancomycin-resistant enterococci.

B E Murray1.   

Abstract

Enterococci have been recognized as an important cause of nosocomial infections for almost 20 years and as a cause of endocarditis for almost a century. While long known for their capacity of displaying multiple antibiotic resistant traits, the extent to which this could occur was not fully appreciated until the emergence of enterococci with acquired resistance to vancomycin; this resistance has been particularly problematic because it often occurs in the uncommon subset of enterococci that are also highly resistant to ampicillin-a combination with devastating therapeutic consequences. The observation that vancomycin resistance can be transferred to and expressed in other gram-positive organisms, for which vancomycin is often considered the primary therapeutic alternative, is a chilling reminder of just how close we may be to a wide array of potentially untreatable "killer" microbes.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9217598     DOI: 10.1016/S0002-9343(99)80270-8

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  35 in total

Review 1.  Vancomycin-resistant enterococci.

Authors:  Y Cetinkaya; P Falk; C G Mayhall
Journal:  Clin Microbiol Rev       Date:  2000-10       Impact factor: 26.132

2.  From vanA Enterococcus hirae to vanA Enterococcus faecium: a study of feed supplementation with avoparcin and tylosin in young chickens.

Authors:  B Robredo; K V Singh; F Baquero; B E Murray; C Torres
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

3.  In-vitro activity of piperacillin/tazobactam relative to other antibiotics against blood culture isolates.

Authors:  M Cormican; G Corbett-Feeney; S Kelly; D Hughes; J Flynn; R N Jones
Journal:  Ir J Med Sci       Date:  1998 Jul-Sep       Impact factor: 1.568

4.  Neonatal septicaemia caused by vancomycin resistant enterococcus faecium-a case report.

Authors:  Shantala Gb; Nagarathnamma T; Pooja Dr; Harsha Tr; Karthik R
Journal:  J Clin Diagn Res       Date:  2014-11-20

Review 5.  VanX, a bacterial D-alanyl-D-alanine dipeptidase: resistance, immunity, or survival function?

Authors:  I A Lessard; C T Walsh
Journal:  Proc Natl Acad Sci U S A       Date:  1999-09-28       Impact factor: 11.205

6.  Treatment of experimental staphylococcal endocarditis due to a strain with reduced susceptibility in vitro to vancomycin: efficacy of ampicillin-sulbactam.

Authors:  M Backo; E Gaenger; A Burkart; Y L Chai; A S Bayer
Journal:  Antimicrob Agents Chemother       Date:  1999-10       Impact factor: 5.191

Review 7.  Total Syntheses of Vancomycin-Related Glycopeptide Antibiotics and Key Analogues.

Authors:  Akinori Okano; Nicholas A Isley; Dale L Boger
Journal:  Chem Rev       Date:  2017-04-24       Impact factor: 60.622

8.  Oral antimicrobial prophylaxis in bone marrow transplant recipients: randomized trial of ciprofloxacin versus ciprofloxacin-vancomycin.

Authors:  C D Ford; W Reilly; J Wood; D C Classen; J P Burke
Journal:  Antimicrob Agents Chemother       Date:  1998-06       Impact factor: 5.191

Review 9.  New antimicrobial agents as therapy for resistant gram-positive cocci.

Authors:  J R Lentino; M Narita; V L Yu
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-01       Impact factor: 3.267

10.  Antagonistic Donor Density Effect Conserved in Multiple Enterococcal Conjugative Plasmids.

Authors:  Arpan Bandyopadhyay; Sofie O'Brien; Kristi L Frank; Gary M Dunny; Wei-Shou Hu
Journal:  Appl Environ Microbiol       Date:  2016-07-15       Impact factor: 4.792

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.